知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.018 秒)

    Formulations for therapeutic viruses having enhanced storage stability
    1.
    发明申请
    Formulations for therapeutic viruses having enhanced storage stability 审中-公开
    具有增强的储存稳定性的治疗性病毒的制剂

    公开(公告)号：US20060205080A1

    公开(公告)日：2006-09-14

    申请号：US11363022

    申请日：2006-02-27

    申请人： David Frey ,  Cassandra Shu

    发明人： David Frey ,  Cassandra Shu

    IPC分类号： C12N15/861

    CPC分类号： C12N15/86 ,  C12N7/00 ,  C12N2710/10321 ,  C12N2710/10343 ,  C12N2710/10351

    摘要： Therapeutic viral formulations having enhanced storage stability are described. The formulations comprise a viral vector in addition to one or more of an aqueous cosolvent, a reversible viral-encoded protease inhibitor and a mild reducing agent or other agent that prevents specific degradation of viral components.

    摘要翻译： 描述了具有增强的储存稳定性的治疗性病毒制剂。 除了一种或多种水溶性共溶剂，可逆病毒编码的蛋白酶抑制剂和温和还原剂或防止病毒组分的特异性降解的其它试剂外，制剂还包含病毒载体。

    Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
    4.
    发明申请
    Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium 审中-公开
    通过膀胱上皮增强治疗剂吸收的组合物和方法

    公开(公告)号：US20080076703A1

    公开(公告)日：2008-03-27

    申请号：US11891659

    申请日：2007-08-09

    申请人： Bahram Memarzadeh ,  Nagarajan Ramesh ,  David Frey ,  DeChao Yu

    发明人： Bahram Memarzadeh ,  Nagarajan Ramesh ,  David Frey ,  DeChao Yu

    IPC分类号： A61K47/08 ,  A61K31/337 ,  A61P13/10 ,  A61P35/00 ,  A61K38/02

    CPC分类号： A61K31/70 ,  A61K31/7012 ,  A61K31/7024 ,  A61K31/715

    摘要： Compositions and methods for enhancing introduction of therapeutic agents into the bladder epithelium for the treatment of bladder diseases and disorders such as bladder cancer are described. According to one method, the luminal surface of the bladder is contacted with a composition comprising a bladder enhancer and a therapeutic agent for the treatment of the bladder disease. According to an alternative method, the luminal surface of the bladder is first contacted with a pretreatment composition comprising a bladder enhancer and subsequently contacted with a composition comprising a therapeutic agent for the treatment of the bladder disease. The transduction enhancing agent can be a mono-, di-, or poly-saccharide having a lipophilic substituent such as n-dodecyl-β-D-maltoside (DDM). Compositions comprising a transduction enhancing agent and a therapeutic agent for the treatment of a bladder disease are also described.

    摘要翻译： 描述了用于增强将治疗剂引入膀胱上皮以治疗膀胱疾病和疾病如膀胱癌的组合物和方法。 根据一种方法，膀胱的管腔表面与包含膀胱增强剂和治疗膀胱疾病的治疗剂的组合物接触。 根据另一种方法，首先将膀胱的腔表面与包含膀胱增强剂的预处理组合物接触，随后与包含用于治疗膀胱疾病的治疗剂的组合物接触。 转导增强剂可以是具有亲脂性取代基如正十二烷基-β-D-麦芽糖苷（DDM）的单糖，二糖或多糖。 还描述了包含转导增强剂和用于治疗膀胱疾病的治疗剂的组合物。